Compare Quest Diagnostics Inc (DGX) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Snap Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Snap Inc trades at $4.68 (market cap $7.87B). The key difference: Quest Diagnostics Inc is far larger — about 2.9× Snap Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| DGX | SNAP | |
|---|---|---|
Market Cap | $22.80B | $7.87B |
Sector | Health | Media |
52-Week High | $216.02 | $10.35 |
52-Week Low | $166.42 | $3.93 |
Enterprise Value | $28.82B | $9.25B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Snap Inc. (SNAP) trades at $4.665, down 0.32% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $5.93B in 2025, with a net loss of $460.49M, though losses have narrowed year-over-year. Recent news highlights the launch of high-priced AR glasses, which has drawn investor skepticism and contributed to stock volatility.
The outlook remains cautious; while cost-cutting and revenue growth offer potential, persistent losses, high debt, and competitive pressures pose significant risks. Analyst consensus is mixed with a $6.82 price target, suggesting moderate upside if execution improves, but the stock faces headwinds from weak profitability and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
